Playback speed
10 seconds
This video is featured in the 2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and Refractory Melanoma"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Douglas Johnson
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Douglas Johnson
478 views
June 7, 2024
Chapters
NADINA Study & Neoadjuvant Therapy
00:00
1L Metastatic: Triplet Immunotherapy & TIL
05:13
Refractory Melanoma: TIL & Viral Therapies
07:01
Survivability & Therapy Sequencing Insights
09:23
Comments 0
Login to view comments.
Click here to Login